1. Hamilton J, Campos R, Creed F. Anxiety, depression and management of medically unexplained symptoms in medical clinics. J R Coll Physicians 1996; 30: 18–21.
2. Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many? The Lancet 1999; 354: 936–9.
3. Egbunike IG, Chaffee BJ. Antidepressants in the management of chronic pain syndromes. Pharmacotherapy 1990; 10 (4): 262–70.
4. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 2000; 32 (5): 305–16.
5. Drossman DA. The functional gastrointestinal disorders and the Rome process. Gastroenterology 2006; 130: 1377–90.
6. Lane RD, Waldstein SR, Critchley HD et al. The Rebirth of Neuroscience in Psychosomatic Medicine, Part II: ClinicalApplications and Implications for Research. Psychosomatic Medicine 2009; 71: 135–51.
7. Wood JD. Neuropathophysiology of functional gastrointestinal disorders. World J Gastroenterol 2007; 13 (9): 1313–32.
8. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994; 8 (4): 409–16.
9. Bixquert-Jime?nez M, Bixquert-Pla L. Antidepressant therapy in functional gastrointestinal disorders. Gastroenterol Hepatol 2005; 28 (8): 485–92.
10. Воробьева О.В. Симбалта – ключевой представитель класса антидепрессантов двойного действия. Лечение нервных болезней. 2005; 16 (2): 33–7.
11. Brennan BP, Fogarty KV, Roberts JL et al. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol 2009; 24 (5): 423–8.